Physician profile
Nehal D Patel
NPI 1619134152
$5,791.24
in general payments reported to CMS, 2019-2025
22 companies · $22.99 in 2025
The $22.99 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $940 · 2021: $947 · 2022: $1,344 · 2023: $1,068 · 2024: $17.99 · 2025: $22.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,217.35 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $793.11 | 2019-2023 | |
| Amgen INC. | $624.11 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.03 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $399.14 | 2019-2023 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $377.96 | 2019-2023 | Farxiga |
| Astellas Pharma US INC | $284.41 | 2019-2020 | |
| Pfizer INC. | $262.40 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $237.49 | 2021-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $205.78 | 2019-2023 | |
| Novo Nordisk INC | $203.72 | 2019-2023 | Ozempic |
| Amarin Pharma, INC. | $202.95 | 2019-2022 | |
| Tactile Systems Technology INC | $114.83 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Boston Scientific Corporation | $97.17 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.81 | 2019-2023 | Lifevest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $51.60 | 2021-2023 | Opsumit, Uptravi |
| Medtronic Vascular, INC. | $49.58 | 2019 | |
| Esperion Therapeutics, INC. | $39.29 | 2023 | Nexletol |
| Janssen Biotech, INC. | $22.99 | 2025 | Tremfya |
| Abbott Laboratories | $16.50 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.83 | 2019 | |
| Medtronic, INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.